PlainBillCongress, translated.Legislation. Context. Public interest.Read twice and referred to the Committee on Foreign Relations.
Congressional Research Service
Version 00 · Introduced in Senate · Sep 30, 2021
Biological Weapons Policy Act of 2021
This bill modifies the Department of State's authorities related to biological and virological weapons and addresses related issues.
The State Department's authority to engage in certain activities (e.g., conduct research and provide grants) related to detecting and reducing certain weapons shall include activities directed at biological and virological weapons.
Showing the opening paragraphs of the official summary.
The bill prohibits using federal funds for research that increases the pathogenicity, contagiousness, or transmissibility of viruses or bacteria if the research involves a foreign entity subject to the jurisdiction of certain countries, including China and Russia.
The President must carry out certain activities related to China's compliance with the Biological Weapons Convention, including engaging with other governments about concerns about such compliance.
The U.S. representative to the United Nations (UN) must advocate to bar representatives from certain countries, including China and Russia, from serving in leadership positions in any UN agency or program with a nexus to certain subjects, such as global health and biosecurity.
The U.S. mission to certain countries must complete an assessment of whether each U.S. government-supported project involving life sciences dual-use research of concern aligns with U.S. national interests.
The Government Accountability Office must report to Congress on (1) U.S. government authorities and processes related to cooperation with other nations in life sciences research that could be weaponized or pose dual-use concerns; and (2) coordination between federal agencies responsible for public health, biomedical research, and national security in the assessment of the security implications of cooperation with other nations on life sciences research.
People & committees
Sen. Risch, James E. [R-ID] · R–ID
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Read twice and referred to the Committee on Foreign Relations.
Introduced in Senate
Primary sources
Text links open the official source. We currently store references to these documents.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Apr 7, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze S.2912 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine S.2912 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine S.2912 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine S.2912 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.